A Shift of Power in Pharmaceuticals
In a tectonic shift of industrial power, drug manufacturers have lost control of the sale of their products to a handful of upstart managed-care companies, which have rapidly taken charge of more than half the nation's $60-billion-a-year drug business. Trying to regain control of their market, some drug companies have acquired managed-care drug companies of their own. On Tuesday, SmithKline Beecham bought Diversified Pharmaceutical Services for $2.3 billion, following the lead of Merck & Company, the world's largest drug maker, which acquired Medco Containment Services last November for $6.6 billion.